A Novel Prediction Tool Based on Large Cohorts to Determine the Cancer-Specific Survival Probability of Patients With Locally Advanced Pancreatic Cancer After Irreversible Electroporation Treatment

Overview

Journal Front Oncol

Specialty Oncology

Date 2020 Jul 23

PMID 32695671

Citations 3

Authors

Chaobin He

Xin Huang

Yu Zhang

Xiaojun Lin

Shengping Li

Affiliations

Soon will be listed here.

Abstract

Irreversible electroporation (IRE) is a novel method which was especially suitable for the treatment of locally advanced pancreatic cancer (LAPC). The purpose of this study was to evaluate probabilities of overall survival (OS) and cancer-specific survival (CSS) in patients with LAPC after IRE treatment and to construct nomograms to predict survival for these patients. Data of patients were retrospectively collected from the Surveillance, Epidemiology, and End Results (SEER) database and medical records of Sun Yat-sen University Cancer Center (SYSUCC). A total of 312 LAPC patients after IRE treatment were included into this study. The 3-year cumulative incidence of cancer-specific mortality for patients with LAPC after IRE treatment was 74.3%. Nomograms for predicting probabilities of OS, CSS, and non-cancer-specific survival (NCSS) were built and calibrated with the concordance index (C-index) and the area under receiver operating characteristic (ROC) curve (AUC). The established nomograms were well-calibrated, with C-indexes of 0.782 for OS prediction, 0.729 for CSS prediction, and 0.730 for NCSS prediction. Compared with the TNM stage system, the established nomograms displayed higher values of AUC and showed better discriminatory power for predicting OS, CSS, and NCSS. These nomograms were well-calibrated and could serve to guide management of LAPC patients after IRE treatment.

Citing Articles

Dendritic cell vaccination combined with irreversible electroporation for treating pancreatic cancer-a narrative review.

Zhang Z, Yu G, Eresen A, Chen Z, Yu Z, Yaghmai V Ann Transl Med. 2024; 12(4):77.

PMID: 39118942 PMC: 11304422. DOI: 10.21037/atm-23-1882.

Development and external validation of a prognostic nomogram to predict survival in patients aged ≥60 years with pancreatic ductal adenocarcinoma.

Zheng B, Ding G, Lu G, Li L Transl Cancer Res. 2024; 13(6):2751-2766.

PMID: 38988930 PMC: 11231776. DOI: 10.21037/tcr-24-5.

A Novel Predictive Tool for Determining the Risk of Early Death From Stage IV Endometrial Carcinoma: A Large Cohort Study.

Song Z, Wang Y, Zhou Y, Zhang D Front Oncol. 2020; 10:620240.

PMID: 33381462 PMC: 7769006. DOI: 10.3389/fonc.2020.620240.

References

He C, Mao Y, Wang J, Duan F, Lin X, Li S . Nomograms predict long-term survival for patients with periampullary adenocarcinoma after pancreatoduodenectomy. BMC Cancer. 2018; 18(1):327. PMC: 5870913. DOI: 10.1186/s12885-018-4240-x. View

Shen W, Sakamoto N, Yang L . Cancer-specific mortality and competing mortality in patients with head and neck squamous cell carcinoma: a competing risk analysis. Ann Surg Oncol. 2014; 22(1):264-71. DOI: 10.1245/s10434-014-3951-8. View

Paiella S, De Pastena M, DOnofrio M, Crino S, Pan T, De Robertis R . Palliative therapy in pancreatic cancer-interventional treatment with radiofrequency ablation/irreversible electroporation. Transl Gastroenterol Hepatol. 2018; 3:80. PMC: 6232064. DOI: 10.21037/tgh.2018.10.05. View

Muss H, Biganzoli L, Sargent D, Aapro M . Adjuvant therapy in the elderly: making the right decision. J Clin Oncol. 2007; 25(14):1870-5. DOI: 10.1200/JCO.2006.10.3457. View

Lin M, Liang S, Wang X, Liang Y, Zhang M, Chen J . Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment. J Cancer Res Clin Oncol. 2017; 143(12):2607-2618. DOI: 10.1007/s00432-017-2513-4. View

Lian M, Perez M, Liu Y, Schootman M, Frisse A, Foldes E . Neighborhood socioeconomic deprivation, tumor subtypes, and causes of death after non-metastatic invasive breast cancer diagnosis: a multilevel competing-risk analysis. Breast Cancer Res Treat. 2014; 147(3):661-70. PMC: 4181526. DOI: 10.1007/s10549-014-3135-z. View

Adamu M, Nitschke P, Petrov P, Rentsch A, Distler M, Reissfelder C . Validation of prognostic risk scores for patients undergoing resection for pancreatic cancer. Pancreatology. 2018; 18(5):585-591. DOI: 10.1016/j.pan.2018.05.005. View

Pu N, Gao S, Xu Y, Zhao G, Lv Y, Nuerxiati A . Alkaline Phosphatase-To-Albumin Ratio as a Prognostic Indicator in Pancreatic Ductal Adenocarcinoma after Curative Resection. J Cancer. 2017; 8(16):3362-3370. PMC: 5665053. DOI: 10.7150/jca.20917. View

Martin 2nd R, Kwon D, Chalikonda S, Sellers M, Kotz E, Scoggins C . Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Ann Surg. 2015; 262(3):486-94. DOI: 10.1097/SLA.0000000000001441. View

10.

Martin 2nd R, McFarland K, Ellis S, Velanovich V . Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma. J Am Coll Surg. 2012; 215(3):361-9. DOI: 10.1016/j.jamcollsurg.2012.05.021. View

11.

Hang J, Wu L, Zhu L, Sun Z, Wang G, Pan J . Prediction of overall survival for metastatic pancreatic cancer: Development and validation of a prognostic nomogram with data from open clinical trial and real-world study. Cancer Med. 2018; 7(7):2974-2984. PMC: 6051216. DOI: 10.1002/cam4.1573. View

12.

Martin 2nd R, McFarland K, Ellis S, Velanovich V . Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival. Ann Surg Oncol. 2012; 20 Suppl 3:S443-9. DOI: 10.1245/s10434-012-2736-1. View

13.

Pencina M, DAgostino R . Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004; 23(13):2109-23. DOI: 10.1002/sim.1802. View

14.

Martin R, Philips P, Ellis S, Hayes D, Bagla S . Irreversible electroporation of unresectable soft tissue tumors with vascular invasion: effective palliation. BMC Cancer. 2014; 14:540. PMC: 4124136. DOI: 10.1186/1471-2407-14-540. View

15.

Narayanan G, Hosein P, Arora G, Barbery K, Froud T, Livingstone A . Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma. J Vasc Interv Radiol. 2012; 23(12):1613-21. DOI: 10.1016/j.jvir.2012.09.012. View

16.

Shen Y, Bai X, Jin G, Zhang Q, Lu J, Qin R . A preoperative nomogram predicts prognosis of up front resectable patients with pancreatic head cancer and suspected venous invasion. HPB (Oxford). 2018; 20(11):1034-1043. DOI: 10.1016/j.hpb.2018.04.010. View

17.

Bower M, Sherwood L, Li Y, Martin R . Irreversible electroporation of the pancreas: definitive local therapy without systemic effects. J Surg Oncol. 2011; 104(1):22-8. DOI: 10.1002/jso.21899. View

18.

Weiss M, Wolfgang C . Irreversible electroporation: a novel therapy for stage III pancreatic cancer. Adv Surg. 2014; 48:253-8. DOI: 10.1016/j.yasu.2014.05.002. View

19.

Porcelli L, Quatrale A, Mantuano P, Leo M, Silvestris N, Rolland J . Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity. Mol Oncol. 2012; 7(3):308-22. PMC: 5528465. DOI: 10.1016/j.molonc.2012.10.002. View

20.

He C, Wang J, Zhang Y, Lin X, Li S . Irreversible electroporation after induction chemotherapy versus chemotherapy alone for patients with locally advanced pancreatic cancer: A propensity score matching analysis. Pancreatology. 2020; 20(3):477-484. DOI: 10.1016/j.pan.2020.02.009. View